Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma
The main purpose of this trial is to investigate and evaluate the efficacy of cryoablation combined with camrelizumab treatment to patients with advanced or inoperable soft tissue sarcomas after standard treatment failure.
| Condition(s) | Soft Tissue Sarcoma (STS), Osteosarcoma |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | The main purpose of this trial is to investigate and evaluate the efficacy of cryoablation combined with camrelizumab treatment to patients with advanced or inoperable soft tissue sarcomas after standard treatment failure. |
| Who can participate | Inclusion Criteria: 1. Before any procedures related to the research program, including screening and evaluation stage, signed informed consent. 2. Age≥14 years old, and≤70 years old ; 3. Pathologically diagnosed as soft tissue sarcomas, and staging for advanced or unresectable patients ; 4. Patients with standard treatment (such as chemotherapy) failure ; 5. No previous treatment with PD-1 antibody ; or those who have previously received PD-1 antibody therapy and progressed at least half a year later; 6. According to the RECIST1.1 standard, there are ≥3 measurable lesions; the distribution sites of multiple lesions are in ≤3 organs (which may include the abdominopelvic cavity, extremities, liver, lungs, pleura, etc.); the size of the target lesions is 1.0 - 5.0 cm. 7. ECOG score 0-1 ( see |
| Ages | 14 Years to 70 Years |
| Sex | All |
| Lead sponsor | Sun Yat-sen University |
| Locations | Guangzhou, Guangdong, China |
| Start date | 2024-11-20 |
| NCT ID | NCT07602049 |
| Official listing | https://clinicaltrials.gov/study/NCT07602049 |